Patents Examined by Fozia Hamud
  • Compositions and methods for targeting type 1 interferon producing cells
    Patent number: 9758585
    Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: September 12, 2017
    Assignee: CSL Limited
    Inventors: Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield, Con Panousis
  • Cytokine-based fusion proteins for treatment of immune disorders
    Patent number: 9745361
    Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: August 29, 2017
    Assignee: East Carolina University
    Inventor: Mark D. Mannie
  • Compositions and methods for treating inflammatory diseases
    Patent number: 9744220
    Abstract: The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF. The invention also provides compositions featuring PDNF, or a fragment thereof, and methods for using such compositions for the proliferation and/or mobilization of a stem cell (e.g., cardiac stem cell) or progenitor cell (e.g., hepatic progenitor cell). In one aspect, the invention provides a method of decreasing inflammation in a nonneuronal tissue of a subject. In another aspect, the invention provides a method of decreasing inflammation in a cardiac, liver, pancreas, or gastrointestinal tissue of a subject. In still another aspect, the invention provides a method of increasing expression of an anti-inflammatory factor in a non-neuronal cell or tissue.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignee: Tufts University
    Inventor: Mercio A. Perrin
  • Method for treating arthritis using IK factor or nucleic acid encoding IK factor
    Patent number: 9737588
    Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: August 22, 2017
    Assignees: CELLINBIO CO., LTD, CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Jae-Hwan Nam, Hye-Lim Park, Dong-Hee Lee
  • Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody
    Patent number: 9725509
    Abstract: The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 8, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith
  • Method of improving patient survivability and quality of life by administering an anti-IL-6 antibody
    Patent number: 9717793
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 1, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Glatiramer acetate human monocytic cell line-based potency assay
    Patent number: 9702866
    Abstract: The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon (IFN?), exposing the cells to a batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine sIL-1Ra or the viability of the cells induced by glatiramer acetate.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: July 11, 2017
    Assignee: SYNTHON B.V.
    Inventors: Sebastianus Martinus Henricus Kolen, Francisca Antoinette Adriana Weijts
  • Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
    Patent number: 9701747
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: July 11, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Anti-ED-A immunoconjugates for inflammatory bowel disease
    Patent number: 9695232
    Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: July 4, 2017
    Assignee: Philogen S.p.A.
    Inventors: Giovanni Neri, Kathrin Schwager, Melanie C. Ruzek, Denise M. O'Hara, Jianqing Chen
  • Tear lipocalin muteins binding IL-4 R alpha
    Patent number: 9687524
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: June 27, 2017
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • IL-17 antagonist antibodies
    Patent number: 9676847
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 13, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Vaccines having an antigen and interleukin-23 as an adjuvant
    Patent number: 9669091
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-23. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 6, 2017
    Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Jian Yan, Matthew Morrow, Bernadette Ferraro, David Hokey
  • GM-CSF and IL-4 conjugates, compositions, and methods related thereto
    Patent number: 9657076
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: May 23, 2017
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Nucleic acid encoding anti-IL13 human antibodies
    Patent number: 9650438
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Generation of neural stem cells from undifferentiated human embryonic stem cells
    Patent number: 9650605
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: May 16, 2017
    Assignee: ES Cell International PTE Ltd.
    Inventor: Benjamin Eithan Reubinoff
  • Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory
    Patent number: 9650439
    Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Franco E. Di Padova, Thomas Huber, Jean-Michel Rene Rondeau
  • IL-33 antagonists and uses thereof
    Patent number: 9637535
    Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie Orengo
  • Use of interleukin-22 in treating viral hepatitis
    Patent number: 9629898
    Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by heptatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: April 25, 2017
    Assignee: Generon (Shanghai) Corporation, LTD.
    Inventors: Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Yuliang Huang
  • Treatment of IgE-mediated disease
    Patent number: 9617325
    Abstract: The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: April 11, 2017
    Assignees: Boston Medical Center Corporation, Trustees of Boston University
    Inventors: Lisa Ganley-Leal, John H. Connor
  • Methods for blocking or reducing binding of interleukin-6 to interleukin-6 receptor
    Patent number: 9617341
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: April 11, 2017
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert